Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment…
